The aim of this study was to investigate whether a combination of nutrients designed to promote gut and brain health also lowers psychological distress. The hypothesis is that a probiotic with fish oil, and glutamine supplement will reduce psychological distress.
Design:
A multiple baseline design was used to collect data from seven naturopathic patients in private naturopathic clinics in Australia. Patients were between 18 and 65 years of age, and had a Kessler-10 (K10) score between 16 and 30 and symptoms associated with mild gastrointestinal discomfort experienced several times most weeks for 3 months. They were randomized into one of three pathways to stagger the introduction of the intervention.
Interventions:
Participants received either a supplement incorporating a probiotic formulation (including Lactobacillus rhamnosus), a glutamine powder formulation, and fish oil, or matched placebos. The primary outcome measure was psychological distress as measured by the K10 scale of psychological distress.
Results:
The data showed a general trend toward lower K10 scores during the active phase compared with the baseline phase, with a marked reduction in the variances between phases. After controlling for time and baseline values, no significant difference between the phases for the K10 and the Perceived Stress Scale was found, but there was still a significant reduction in symptoms on the Gastrointestinal Symptom Rating Scale.
Conclusions:
A combination of a probiotic formulation, a glutamine powder formulation, and fish oil did not affect psychological distress and perceived stress, but had a significant beneficial effect on gastrointestinal symptoms in patients with high distress and concurrent gut symptomology.
Clinical trial registration number:
ACTRN12620000928910.
Get full access to this article
View all access options for this article.
References
1.
Australian Government Department of Health. Prevalence of Mental Disorders in the Australian Population; 2009. Available from: https://www1.health.gov.au/internet/publications/publishing.nsf/Content/mental-pubs-m-mhaust2-toc∼mental-pubs-m-mhaust2-hig∼mental-pubs-m-mhaust2-hig-pre [Last accessed: January10, 2021].
2.
Australian Government Department of Defence. 2010 ADF Mental Health Prevalence and Wellbeing Study Executive Report. Canberra; 2010. Available from: www.defence.gov.au/Health/DMH/MentalHealthReformProgram.asp#3 [Last accessed: March16, 2018].
3.
ClarkeG, CryanJF, DinanTG, et al.Review article: Probiotics for the treatment of irritable bowel syndrome—Focus on lactic acid bacteria. Aliment Pharmacol Ther, 2012; 35(4):403–413; doi: 10.1111/j.1365-2036.2011.04965.x
4.
VerdinoJ.The third tier in treatment: Attending to the growing connection between gut health and emotional well-being. Health Psychol Open, 2017; 4(2):2055102917724335; doi: 10.1177/2055102917724335
5.
FosterJA, McVay NeufeldK-A. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci, 2013; 36(5):305–312.
6.
GaffeyAE, BergemanCS, ClarkLA, et al.Aging and the HPA axis: Stress and resilience in older adults. Neurosci Biobehav Rev, 2016; 68:928–945; doi: 10.1016/j.neubiorev.2016.05.036
7.
BlackPH.The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immunity, 2003; 17(5):350–364.
8.
SeemanTE, RobbinsRJ. Aging and hypothalamic-pituitary-adrenal response to challenge in humans. Endocrine Rev, 1994; 15(2):233–260.
9.
SternbergEM, HillJM, ChrousosGP, et al.Inflammatory mediator-induced hypthalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci U S A, 1989; 86:2374–2378.
10.
GoldPW.The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry, 2015; 20(1):32–47; doi: 10.1038/mp.2014.163
11.
KarinO, RazM, TendlerA, et al.A new model for the HPA axis explains dysregulation of stress hormones on the timescale of weeks. Mol Syst Biol, 2020; 16(7):e9510.
12.
SilvermanMN, SternbergEM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci, 2012; 1261:55–63; doi: 10.1111/j.1749-6632.2012.06633.x
13.
YudkinJS, KumariM, HumphriesSE, et al.Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?. Atherosclerosis, 2000; 148(2):209–214; doi: S0021915099004633 [pii]
14.
FosterJA, RinamanL, CryanJF. Stress & the gut-brain axis: Regulation by the microbiome. Neurobiol Stress, 2017; 7:124–136; doi: 10.1016/j.ynstr.2017.03.001
15.
JackaFN.Nutritional psychiatry: Where to next?. EBioMedicine, 2017; 17:24–29; doi: 10.1016/j.ebiom.2017.02.020
16.
NishimuraM, OhkawaraT, TetsukaK, et al.Effects of yogurt containing Lactobacillus plantarum HOKKAIDA on immune function and stress markers. J Tradit Complement Med, 2016; 6:275–280.
17.
ThomasS, IzardJ, WalshE, et al.The host microbiome regulates and maintains human health: A primer and perspective for non-microbiologists. Cancer Res, 2017; 77(8):1783–1812; doi: 10.1158/0008-5472.CAN-16-2929
18.
OhiraT, AritaM, OmoriK, et al.Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem, 285(5):3451–3461.
19.
BonfrateL, TackJ, GrattaglianoI, et al.Microbiota in health and irritable bowel syndrome: Current knowledge, perspectives and therapeutic options. Scand J Gastroenterol, 2013; 48(9):995–1009; doi: 10.3109/00365521.2013.799220
20.
Bruce-KellerA, SalbaumJ, BerthoudH-R. Harnessing gut microbes for mental health: Getting from here to there. Biol Psychiatry, 2018; 8:214–223.
21.
BerrickP, CollinsS, VerduE. Microbes and the gut-brain axis. Neurogastroenterol Motil, 2012; 24:405–413.
22.
SteenbergenL, SellaroR, van HemertS, et al.A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain Behav Immunity, 2015; 48:258–264.
23.
ReisD, IlardiS, PuntE. The anxiolytic effect of probiotics: A systematic review and meta-analysis of the clinical and preclinical literature. PLoS One, 2018; 13(6):e0199041.
24.
RitenbaughC, VerhoefM, FleishmanS, et al.Whole systems research: a discipline for studying complementary and alternative medicine. Altern Ther Health Med, 2003; 93:186–189.
25.
IjazN, RiouxJ, ElderC, et al.Whole systems research methods in health care: A scoping review. J Altern Complement Med, 2019; 25(Suppl 1):S21–S51; doi: 10.1089/acm.2018.0499
26.
MyersSP, VigarV. The state of evience for whole-system, multi-modality naturopathic medicine: A systematic scoping review. J Altern Complement Med, 2019; 25(2):141–168.
27.
Group. OLoEW. The Oxford 2011 Levels of Evidence; 2011. Available from: www.cebm.net/index.aspx?o=5653 [Last accessed: June7, 2018].
28.
LaiW-D, TungT-H, TengC-Y, et al.Fish oil ameliorates neuropsychiatric behaviors and gut dysbiosis by elevating selected microbiota–derived metabolites and tissue tight junctions in rats under chronic sleep deprivation. Food Funct, 2022; 13(5):2662–2680.
29.
AbdellahSA, GalC, LaterzaL, et al.Effect of a multistrain probiotic on leaky gut in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): A pilot study. Dig Dis, 2022. [Epub ahead of print]; doi: 10.1159/000526712
30.
VaresiA, CampagnoliLIM, FahmidehF, et al.The interplay between gut microbiota and Parkinson's disease: Implications on diagnosis and treatment. Int J Mol Sci, 2022; 23(20):12289.
31.
ChantlerS, GriffithsA, MatuJ, et al.A systematic review: Role of dietary supplements on markers of exercise-associated gut damage and permeability. PLoS One, 2022; 17(4):e0266379.
32.
TateR, PerdicesM.N-of-1 Trials in the Behavioural Sciences. In: The Essential Guide to N-of-1 Trials in Health. (NiklesJ, MitchellG. eds.) Springer: Dordrecht; 2015; pp. 19–41.
33.
CaoJ, SchwichtenbergKA, HansonNQ, et al.Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem, 2006; 52(12):2265–2272; doi: 10.1373/clinchem.2006.072322
34.
HemarajataP, VersalovicJ. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. Ther Adv Gastroenterol, 2013; 6(1):39–51; doi: 10.1177/1756283X12459294
35.
KesslerRC, BarkerPR, ColpeLJ, et al.Screening for serious mental illness in the general population. Arch Gen Psychiatry, 2003; 60(2):184–189.
36.
RevickiDA, WoodM, WiklundI, et al.Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res, 1997; 7(1):75–83; doi: 10.1023/a:1008841022998
37.
SvedlundJ, SjodinMD, DotevallG. GSRS-A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci, 1988; 33:12–134.
38.
CohenS, KamarckT, MermelsteinR. A global measure of perceived stress. J Health Soc Behav, 1983; 24(4):385–396.
39.
RobertiJ, HarringtonL, StorchE. Further psychometric support for the 10-item version of the Perceived Stress Scale. J Am Couns Assoc, 2006; 9(Fall):135–147.
40.
LeeE-H.Review of the psychometric evidence of the Perceived Stress Scale. Asian Nurs Res, 2012; 6:121–127.
41.
CurranSL, AndrykowskiMA, StudtsJL. Short form of the profile of mood states (POMS-SF): Psychometric information. Psychol Assess, 1995; 7(1):80–83.
42.
GroveJR, PrapavessisH. Preliminary evidence for the reliability and validity of an abbreviated profile of mood states. Int J Sport Psychol, 1992; 23(2):93–109.
43.
FasanoA.Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci, 2012; 1258(1):25–33; doi: 10.1111/j.1749-6632.2012.06538.x
44.
ShamseerL, SampsonM, BukutuC, et al.CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. J Clin Epidemio, 2016; 76:18–46; doi: 10.1016/j.jclinepi.2015.05.018
45.
BhattA.Evolution of clinical research: A history before and beyond James Lind. Perspect Clin Res, 2010; 1(1):6–10.
46.
McFarlandLV, KarakanT, KaratasA. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine, 2021; 41:101154; doi: 10.1016/j.eclinm.2021.101154
47.
BlandJM, AltmanDG. Regression towards the mean. BMJ, 1994; 308(6942):1499.
48.
PocockSJ, AssmannSE, EnosLE, et al.Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat Med, 2002; 21(19):2917–2930.
49.
MagneF, GottelandM, GauthierL, et al.The Firmicutes/Bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients?. Nutrients, 2020; 12(5):1474; doi: 10.3390/nu12051474
50.
WexlerHM.Bacteroides: The good, the bad, and the nitty-gritty. Clin Microbiol Rev, 2007; 20(4):593–621.
51.
ToscanoM, De GrandiR, StronatiL, et al.Effect of Lactobacillus rhamnosus HN001 and Bifidobacterium longum BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study. World J Gastroenterol, 2017; 23(15):2608–2704; doi: 10.3748/wjg.v23.i15.2696
52.
CostantiniL, MolinariR, FarinonB, et al.Impact of omega-3 fatty acids on the gut microbiota. Int J Mol Sci, 2017; 18(12):2645; doi: 10.3390/ijms18122645
53.
PlavnickJB, FerreriSJ. Single-case experimental designs in educational research: A methodology for causal analyses in teaching and learning. Educ Psychol Rev, 2013; 25:549–569; doi: 10.1007/s10648-013-9230-6
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
